This CDC MMWR summarizes the clinical and epidemiologic characteristics of people with a severe allergic reaction known as anaphylaxis who received the first dose of Moderna COVID-19 vaccine in the United States during the first three weeks of vaccine administration. Early safety monitoring of the Moderna COVID-19 vaccine detected 10 people with anaphylaxis among more than 4 million first doses of Moderna COVID-19 vaccine that were administered. Among those with follow-up information available, all recovered or were discharged home.
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine
Jan 22, 2021 | Beth Hess
Related Posts
- Community Health Community Resilience COVID-19 Performance Improvement
NACCHO’s COVID Workforce Project: Leveraging Community...
At Oneida County Health Department, cooperation is baked into daily operations;...
Apr 11, 2024 | Andrea Grenadier
NACCHO’s COVID Workforce Project: Leveraging Community...
- Tools & Resources Communications & Public Relations Public Health and Homelessness
NACCHO Social Media Strategy - National Public Health...
National Public Health Week (NPHW) was from April 1 to April 7, 2024. NACCHO...
Apr 11, 2024 | Emma James